On October 31, 2023 Lirum Therapeutics, Inc. ("Lirum"), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, reported the presentation of positive data at the 2023 Connective Tissue Oncology Society meeting in Dublin, Ireland (Press release, Lirum Therapeutics, OCT 31, 2023, View Source [SID1234651603]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R),demonstrated potent anti-tumor activity against cell lines with well-established IGF-1R pathway involvement, including pediatric sarcomas. These include cancers with known genetic alterations affecting the IGF-1R pathway and/or with high IGF-1R expression such as Ewing’s and related sarcomas, rhabdomyosarcoma, and osteosarcoma.
LX-101 was active against a variety of pediatric cancer cell lines including Ewing’s sarcoma (with EWSR1-FLI1 and EWSR1-ERG gene fusions), alveolar rhabdomyosarcoma (with the PAX3-FOXO1 gene fusion), and osteosarcoma. The poster will be presented on November 2, 2023 at 5:30 PM IST (local time) and will be available on the Lirum website (www.lirumtx.com) under the Investors and Media tab.
Given these promising results, and the existing clinical data, Lirum is planning new clinical trials with LX-101 in pediatric and adult oncologic indications that carry strong ties to the IGF-1/IGF-1R pathway. In parallel, Lirum is also planning to develop LX-101 in certain autoimmune diseases, such as thyroid eye disease (TED), where IGF-1R has been clinically and commercially validated.
About LX-101
Lirum’s lead product candidate, LX-101, is a novel, clinical-stage, next generation, precision-engineered, payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R). The IGF-1/IGF-1R pathway has been implicated in a host of malignancies and autoimmune diseases, including thyroid eye disease (TED), and which Lirum believes represents a scientifically and medically rational target in both oncology and autoimmune indications. LX-101 consists of a proprietary, engineered variant of the IGF-1 ligand, conjugated to a cytotoxic payload, methotrexate, and harbors a novel and differentiated mechanism of action versus current and past IGF-1R targeted approaches.
LX-101 (formerly 765IGF-MTX) has been evaluated in Phase 1 clinical trials of patients with advanced, pretreated solid and hematologic cancers. It was found to be well-tolerated and demonstrated single agent activity. No dose limiting toxicity or maximum tolerated dose were reached, and Lirum intends to explore further dose escalation and schedule optimization as well as focus on those indications with strong ties to the IGF-1/IGF-1R pathway.